Money

Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-™T) published in Nature Medicine, a top international medical journal




Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-™T) published in Nature Medicine, a top international medical journal



READ SOURCE

ALSO READ  BlackRock: World's largest fund manager to start selling coal investments to tackle climate crisis

This website uses cookies. By continuing to use this site, you accept our use of cookies.